ATE505203T1 - Pharmazeutische kombination aus aliskiren und valsartan - Google Patents
Pharmazeutische kombination aus aliskiren und valsartanInfo
- Publication number
- ATE505203T1 ATE505203T1 AT08835893T AT08835893T ATE505203T1 AT E505203 T1 ATE505203 T1 AT E505203T1 AT 08835893 T AT08835893 T AT 08835893T AT 08835893 T AT08835893 T AT 08835893T AT E505203 T1 ATE505203 T1 AT E505203T1
- Authority
- AT
- Austria
- Prior art keywords
- aliskiren
- valsartan
- minutes
- dose combination
- fixed dose
- Prior art date
Links
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 title abstract 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 title abstract 3
- 229960004601 aliskiren Drugs 0.000 title abstract 3
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 3
- 229960004699 valsartan Drugs 0.000 title abstract 3
- 229940000425 combination drug Drugs 0.000 abstract 3
- 238000004090 dissolution Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97590507P | 2007-09-28 | 2007-09-28 | |
| PCT/US2008/077417 WO2009045796A1 (en) | 2007-09-28 | 2008-09-24 | Pharmaceutical combination of aliskiren and valsartan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE505203T1 true ATE505203T1 (de) | 2011-04-15 |
Family
ID=40394241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08835893T ATE505203T1 (de) | 2007-09-28 | 2008-09-24 | Pharmazeutische kombination aus aliskiren und valsartan |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100247645A1 (de) |
| EP (1) | EP2205279B1 (de) |
| JP (1) | JP2010540548A (de) |
| KR (1) | KR20100059912A (de) |
| CN (1) | CN101808665A (de) |
| AT (1) | ATE505203T1 (de) |
| AU (1) | AU2008309059A1 (de) |
| BR (1) | BRPI0817275A2 (de) |
| CA (1) | CA2697437A1 (de) |
| DE (1) | DE602008006243D1 (de) |
| ES (1) | ES2364538T3 (de) |
| MX (1) | MX2010003439A (de) |
| PL (1) | PL2205279T3 (de) |
| PT (1) | PT2205279E (de) |
| RU (1) | RU2010116526A (de) |
| WO (1) | WO2009045796A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2535090C2 (ru) * | 2009-01-28 | 2014-12-10 | Новартис Аг | Галеновы препараты органических соединений |
| US20120009257A1 (en) * | 2009-03-20 | 2012-01-12 | Indrajit Ghosh | Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren |
| WO2011116115A1 (en) * | 2010-03-16 | 2011-09-22 | Novartis Ag | Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing |
| SG174658A1 (en) * | 2010-04-01 | 2011-10-28 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
| BR112013028755A2 (pt) | 2011-05-10 | 2017-01-31 | Theravida Inc | combinações de solifenacina e estimulantes salivares para o tratamento de bexiga hiperativa |
| CN102247344A (zh) * | 2011-05-30 | 2011-11-23 | 北京阜康仁生物制药科技有限公司 | 一种新型降血压组合物 |
| CN102626395B (zh) * | 2012-04-19 | 2014-02-26 | 海南美兰史克制药有限公司 | 一种阿利克仑缬沙坦药物组合物脂质体固体制剂 |
| DK2844233T3 (da) * | 2012-05-01 | 2020-07-13 | Althera Life Sciences Llc | Oral tabletformulering bestående af en fastsat kombination af rosuvastatin og ezetimib til behandling af hyperlipidæmi og kardiovaskulære sygdomme |
| US10376470B2 (en) * | 2012-05-01 | 2019-08-13 | Althera Life Sciences, Llc | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
| WO2013166114A1 (en) * | 2012-05-01 | 2013-11-07 | Althera Life Sciences, Llc | Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe |
| EP3405191B1 (de) | 2016-01-20 | 2025-02-19 | TheraVida, Inc. | Zusammensetzungen zur anwendung für der behandlung von hyperhidrose |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| AR048431A1 (es) * | 2004-03-17 | 2006-04-26 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| BRPI0516128A (pt) * | 2004-10-08 | 2008-08-26 | Novartis Ag | uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica |
| JP2008538549A (ja) * | 2005-03-22 | 2008-10-30 | ノバルティス アクチエンゲゼルシャフト | 高血圧剤としてのアリスキレンの有効性に関するバイオマーカー |
| TWI405580B (zh) * | 2005-06-27 | 2013-08-21 | Sankyo Co | 含有血管收縮素ｉｉ接受器拮抗劑及鈣通道阻斷劑之醫藥調配物 |
-
2008
- 2008-09-24 PT PT08835893T patent/PT2205279E/pt unknown
- 2008-09-24 WO PCT/US2008/077417 patent/WO2009045796A1/en not_active Ceased
- 2008-09-24 AU AU2008309059A patent/AU2008309059A1/en not_active Abandoned
- 2008-09-24 CA CA2697437A patent/CA2697437A1/en not_active Abandoned
- 2008-09-24 US US12/679,052 patent/US20100247645A1/en not_active Abandoned
- 2008-09-24 JP JP2010527092A patent/JP2010540548A/ja active Pending
- 2008-09-24 PL PL08835893T patent/PL2205279T3/pl unknown
- 2008-09-24 BR BRPI0817275-7A patent/BRPI0817275A2/pt not_active IP Right Cessation
- 2008-09-24 AT AT08835893T patent/ATE505203T1/de active
- 2008-09-24 MX MX2010003439A patent/MX2010003439A/es active IP Right Grant
- 2008-09-24 EP EP08835893A patent/EP2205279B1/de not_active Not-in-force
- 2008-09-24 CN CN200880108475A patent/CN101808665A/zh active Pending
- 2008-09-24 ES ES08835893T patent/ES2364538T3/es active Active
- 2008-09-24 DE DE602008006243T patent/DE602008006243D1/de active Active
- 2008-09-24 RU RU2010116526/15A patent/RU2010116526A/ru not_active Application Discontinuation
- 2008-09-24 KR KR1020107006602A patent/KR20100059912A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0817275A2 (pt) | 2015-06-16 |
| EP2205279A1 (de) | 2010-07-14 |
| JP2010540548A (ja) | 2010-12-24 |
| AU2008309059A1 (en) | 2009-04-09 |
| RU2010116526A (ru) | 2011-11-10 |
| PT2205279E (pt) | 2011-07-11 |
| KR20100059912A (ko) | 2010-06-04 |
| CA2697437A1 (en) | 2009-04-09 |
| DE602008006243D1 (de) | 2011-05-26 |
| ES2364538T3 (es) | 2011-09-06 |
| EP2205279B1 (de) | 2011-04-13 |
| CN101808665A (zh) | 2010-08-18 |
| WO2009045796A1 (en) | 2009-04-09 |
| PL2205279T3 (pl) | 2011-09-30 |
| US20100247645A1 (en) | 2010-09-30 |
| MX2010003439A (es) | 2010-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
| TN2010000135A1 (en) | Galenical formulations of organic compounds | |
| ECSP077999A (es) | Formulaciones de una sal de bupropion de liberación modificada | |
| CY1111470T1 (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α | |
| ATE540680T1 (de) | Pharmazeutische aripiprazol-zusammensetzungen | |
| EP1635762A4 (de) | Niedrigdosierte pharmazeutische pulver zur inhalation | |
| JP2007527914A5 (de) | ||
| IL183357A0 (en) | Oral medicament for the modified release of at least one active principle, in multimicrocapsule form | |
| CO6440564A2 (es) | Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona | |
| NZ628513A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
| MX2009004017A (es) | Usos de los compuestos carboxi-amido triazol y sus sales. | |
| UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
| BRPI1009392A2 (pt) | "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica." | |
| CL2012003012A1 (es) | Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion. | |
| WO2008003050A3 (en) | Gallium nitrate formulations | |
| IL187632A (en) | 17 – Ethinyl – 17 – Hydroxy – 13 – Methyl – 17,16,15,14,13,12,11,9,8,7 – Dachahydro – 6 h– Cyclopentane [a] Penanthran – 3 – Ilmethyl ester of acetoxy acid Acetic, a pharmaceutical dosage unit containing it and its use in the preparation of a contraceptive | |
| AR054595A1 (es) | Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis | |
| JO3239B1 (ar) | تركيبات جالينية من مركبات عضوية | |
| WO2005120518A3 (en) | Use of atp analogues for treatment of cardiovascular diseases | |
| AR067351A1 (es) | Combinacion de picotamida con nafronil | |
| MXPA05007253A (es) | Sales novedosas de derivados anticonvulsivantes. | |
| TN2011000100A1 (en) | Galenical formulations of organic compounds | |
| ZA201005394B (en) | 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid y-lactone derivative,use thereof,and medicament containing said derivative | |
| WO2007071721A3 (en) | Ginger extract for inhibiting human drug transporters | |
| MX2011009846A (es) | Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 2205279 Country of ref document: EP |